The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported. Read the full story on the …

The Journal of Medicinal Chemistry has published a Virtual Issue highlighting the accomplishments of Co-Editors in Chief Gunda Georg and Shaomeng Wang as well as an …

The Institute for Therapeutics Discovery and Development (ITDD) has been awarded a new NIH contract entitled "Support for NCATS Medicinal Chemistry for Lead Optimization". The objective of this contract is to support the NIH National Center for Advanced Translational Sciences (NCATS) drug…

Our Leadership


Gunda I. Georg, Ph.D.

Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair

Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures


Vadim J. Gurvich, Ph.D., M.B.A.

Associate Director, Institute for Therapeutics Discovery and Development
Director, Chemical Process Development Core


Michael A. Walters, Ph.D.

Director, Lead and Probe Discovery Core
Institute for Therapeutics Discovery and Development